Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $78.8 million.

  • Lyell Immunopharma's Total Liabilities fell 1092.89% to $78.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.8 million, marking a year-over-year decrease of 1092.89%. This contributed to the annual value of $108.0 million for FY2024, which is 1362.9% up from last year.
  • Per Lyell Immunopharma's latest filing, its Total Liabilities stood at $78.8 million for Q3 2025, which was down 1092.89% from $86.5 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Total Liabilities ranged from a high of $334.0 million in Q1 2021 and a low of $78.8 million during Q3 2025
  • For the 5-year period, Lyell Immunopharma's Total Liabilities averaged around $135.7 million, with its median value being $98.5 million (2023).
  • In the last 5 years, Lyell Immunopharma's Total Liabilities plummeted by 4937.28% in 2023 and then skyrocketed by 1362.9% in 2024.
  • Lyell Immunopharma's Total Liabilities (Quarter) stood at $197.6 million in 2021, then tumbled by 47.22% to $104.3 million in 2022, then fell by 8.85% to $95.1 million in 2023, then increased by 13.63% to $108.0 million in 2024, then fell by 27.02% to $78.8 million in 2025.
  • Its Total Liabilities was $78.8 million in Q3 2025, compared to $86.5 million in Q2 2025 and $93.3 million in Q1 2025.